Andersson B, Strömblad S O, Lomsky M, Waagstein F
Wallenberg Laboratory for Cardiovascular Research, Department of Cardiology, University Hospital, Göteborg, Sweden.
Eur Heart J. 1999 Apr;20(8):575-83. doi: 10.1053/euhj.1998.1315.
To investigate whether a low heart rate is necessary to maintain improvement in myocardial function after long-term treatment with a beta-blocker in patients with heart failure.
Forty-eight patients with congestive heart failure were investigated: 30 patients with dilated cardiomyopathy participating in a placebo-controlled trial (15 on placebo, 15 on metoprolol), and 18 patients treated by metoprolol in an open protocol. Investigations of spontaneous heart rate and of matched paced heart rates were performed at baseline and after 3, 6 and 12 months of follow-up by radionuclide angiography. There were significant signs of improvement in systolic indices of the spontaneous heart rate in the metoprolol-treated group (peak ejection rate: 0.98 to 1.32 end-diastolic volume.s-1, P = 0.015) as compared to placebo (1.14 to 1.19 end-diastolic volume.s-1, not significant). Similar effects were observed during the matched paced heart rate (peak ejection rate: metoprolol 0.91 to 1.38 end-diastolic volume.s-1, P = 0.037; placebo 1.22 to 1.12 end-diastolic volume.s-1, not significant). No effects were observed in the early peak filling rate. Left ventricular volumes decreased during metoprolol treatment, both for the spontaneous heart rate and during matched pacing.
These data imply that beta-blocker treatment improves the force-frequency relationship of myocardial performance. A lower heart rate is not necessary to maintain cardiac function on a short-term basis, once myocardial recovery has occurred.
研究在心力衰竭患者中,长期使用β受体阻滞剂治疗后,低心率是否是维持心肌功能改善所必需的。
对48例充血性心力衰竭患者进行了研究:30例扩张型心肌病患者参与了一项安慰剂对照试验(15例服用安慰剂,15例服用美托洛尔),18例患者采用开放方案接受美托洛尔治疗。在基线以及随访3、6和12个月后,通过放射性核素血管造影对静息心率和匹配的起搏心率进行了检测。与安慰剂组(从1.14至1.19舒张末期容积·秒-1,无显著性差异)相比,美托洛尔治疗组静息心率的收缩指标有显著改善迹象(峰值射血率:从0.98至1.32舒张末期容积·秒-1,P = 0.015)。在匹配的起搏心率期间也观察到了类似的效果(峰值射血率:美托洛尔组从0.91至1.38舒张末期容积·秒-1,P = 0.037;安慰剂组从1.22至1.12舒张末期容积·秒-1,无显著性差异)。在早期峰值充盈率方面未观察到影响。在美托洛尔治疗期间,无论是静息心率还是匹配起搏时,左心室容积均减小。
这些数据表明β受体阻滞剂治疗可改善心肌性能的力-频率关系。一旦心肌恢复,短期内维持心脏功能并不需要较低的心率。